COL6A1 and myopathy: In the last two decades, much effort was spent on the elucidation of the pathogenic mechanisms underlying ColVI‐related myopathies, also by taking advantage of the ColVI null (Col6a1−/−) mouse model,1 in order to identify druggable targets for prospective therapies.2, 3, 4